Marty Makary resigned Tuesday as commissioner of the Food and Drug Administration, ending a 13-month tenure marked by conflicts with the Trump administration over regulatory policies. President Trump confirmed the resignation, which followed weeks of mounting pressure on the agency chief.

Kyle Diamantas, previously the FDA's top food official responsible for setting strategic direction and operations for U.S. food policy, will serve as acting commissioner, according to reports. Diamantas had been overseeing the agency's food safety and policy initiatives before his appointment to the interim role.

Makary's departure came amid disagreements with the administration over regulatory decisions, particularly regarding flavored vaping products. The New York Times reported that Makary privately opposed the administration's decision to approve flavored vapes, creating tension between the commissioner and White House officials.

During his tenure, Makary faced criticism from multiple quarters, including Congress, industry groups, and public health advocates. His leadership coincided with ongoing debates over the FDA's regulatory approach across various sectors, from tobacco products to pharmaceutical approvals.

The resignation occurs as the FDA continues to navigate complex regulatory challenges, including oversight of emerging tobacco products and ongoing safety monitoring of medical treatments. The agency has faced scrutiny over its handling of various public health issues during Makary's time in office.

The transition comes at a critical time for the agency, which oversees food safety, drug approvals, and tobacco regulation affecting millions of Americans. Diamantas will lead the organization while the administration considers a permanent replacement for the commissioner position.